Feline penile erection induced by topical glans penis application of combination alprostadil and SEPA (Topiglan)

International Journal of Impotence Research

Volumn 16, Issue 1, 2004, Pages 73-77

  Usta, M F ^a   Sanabriav, J ^a   Bivalacqua, T J ^a   Hellstrom, W J G ^a,b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cat; Erectile dysfunction; PGE1; Topical treatment

Indexed keywords

PAPAVERINE; PENETRATION ENHANCING AGENT; PHENTOLAMINE; PLACEBO; PROSTAGLANDIN E1; SILDENAFIL; SOFT ENHANCEMENT OF PERCUTANEOUS ABSORPTION; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MONITORING; CAT; CONTROLLED STUDY; CREAM; DOSE RESPONSE; DRUG EFFICACY; MALE; NONHUMAN; PENIS ERECTION; PENIS GLANS; PRESSURE MEASUREMENT; PRIORITY JOURNAL; SKIN ABSORPTION;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, TOPICAL; ALPROSTADIL; ANIMALS; BLOOD PRESSURE; CATS; DIOXOLANES; GELS; MALE; MODELS, ANIMAL; MUSCLE, SMOOTH; PENILE ERECTION; VASODILATOR AGENTS;

EID: 1642565445     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901145     Document Type: Article

References (19)

1. NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993; 270: 83-90.
2. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-1813.
3. Melman A, Rehman J. Pathophysiology of erectile dysfunction. Mol Urol 1999; 3: 87-102.
4. Levine LA. Diagnosis and treatment of erectile dysfunction. Am J Med 2000; 109: 3S-30S.
5. Carson CC. Oral and injectable medications for the treatment of erectile dysfunction. Curr Urol Rep 2000; 1: 307-312.
6. Yap RL, McVary KT. Topical agents and erectile dysfunction: is there a place? Curr Urol Rep 2002; 3: 471-476.
7. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155: 802-815.
8. Goldstein I, Payton TR, Scheichter PJ. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology 2001; 57: 301-305.
9. McMahon CG. Topiglan MacroChem. Curr Opin Investig Drugs 2002; 3: 602-606.
10. Bivalacqua TJ et al. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE4). J Urol 1999; 162: 1848-1855.
11. Bivalacqua TJ et al. Feline penile erection induced by transurethral administration of sodium nitroprusside. Urol Res 1999; 27: 432-436.
12. McVary KT, Polepalle S, Riggi S, Pelham RW. Topical prostaglandin E1 Sepa gel for the treatment of erectile dysfunction. J Urol 1999; 162: 726-731.
13. Berner B, John VA. Pharmacokinetic characterization of transdermal delivery systems. Clin Pharmacokinet 1994; 126: 121-134.
14. Sharlip ID. Evaluation and nonsurgical management of erectile dysfunction. Urol Clin North Am 1998; 25: 647-659.
15. Engel JD, McVary KT. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy. Urology 1998; 15: 687-692.
16. Nunez BD, Anderson DC. Nitroglycerin ointment in the treatment of impotence. J Urol 1993; 150: 1241-1243.
17. Cavallini G. Minoxidil versus nitroglycerin: a prospective double-blind conrolled trial in transcutaneous erection facilitation for organic impotence. J Urol 1991; 146: 50-53.
18. Gomaa A et al. Topical treatment of erectile dysfunction: randomized double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate. Br J Med 1996; 312: 1512-1515.
19. Gozes I, Fridkin M. A fatty neuropeptide. Potential drug for noninvasive impotence treatment in rat model. J Clin Invest 1992; 90: 810-814.